NEW YORK, June 24 (GenomeWeb News) - Cepheid has licensed several PCR-related patents from Roche for in vitro diagnostic products, the Sunnyvale, Calif.-based company said today.
The non-exclusive license comprises Roche patents covering the PCR process, reverse transcription-based methods, nucleic acid quantification methods, real-time PCR detection, and methods for the detection of viral and cancer targets.
Cepheid is permitted to make, use, and sell products based on these technologies for in vitro human diagnostics, except for human identify testing and pathogen detection for blood bank screening and plasma fractionation. Cepheid will pay Roche a licensing fee and ongoing royalties on sales of relevant products.
Yesterday, Cepheid said it has expanded its license to Applera's PCR patents to include real-time PCR.